ClinicalTrials.gg

Cerebral Palsy clinical trials

Its pipeline, or its studies — you choose. Free with an account during the beta.

The registry lists 1,941 studies for Cerebral Palsy across more than 10 countries. 459 are recruiting or about to start. 1,661 of them are mainly about Cerebral Palsy (how this is decided). Per ClinicalTrials.gov, last updated 2026-11-17. Counting its narrower condition Cerebral palsy, spastic, diplegic too: 1,949 studies, 460 open.

ClinicalTrials.gov finds 2,633 studies for Cerebral Palsy. How that becomes 1,939 here

This page counts the studies the registry files under Cerebral Palsy, and those it files under no condition that list Cerebral Palsythemselves. Each study its search finds is placed by how the registry filed it and by the conditions it lists. ClinicalTrials.gov counts as of Nov 16, 2026. How condition pages count

  1. 2,633Found by its condition searchIt reads the conditions a study lists and their synonyms, and also titles and keywords.
  2. −8Filed under a narrower condition, counted on its own pageCerebral palsy, spastic, diplegic 8
  3. −29List Cerebral Palsy as a condition, but the registry did not file them under itMost often written as “Hemiplegic Cerebral Palsy” (8), “Ataxic Cerebral Palsy” (5), and “Cerebral Palsy Children” (2). The registry filed them under other conditions only, most often Hemiplegia (7) and Cerebral Palsy, Ataxic, Autosomal Recessive (6).
  4. −657Match it another way61 name it in the title, 4 in a keyword, and 592 by a synonym or other text the search reads.
  5. 1,939The count on this page92 of them list Cerebral Palsy in their own words; the registry filed them under no condition.

Status

Completed
1,111
Recruiting
270
Status unknown
222
Not yet recruiting
158
Active, not recruiting
75
Terminated
43

Phase

Phase 2
80
Phase 1
54
Phase 3
54
Phase 4
27
Early Phase 1
10

Where

United States
372
Turkey
328
Pakistan
196
Egypt
159
France
91
Canada
82

Who develops what

Add Cerebral Palsy to watchlistPro · free during the betaEvery Monday by email · turn it off any time

Every program with a company-led study here in the last two years, whatever its size: 1 program from 1 company, 1 with this as their studies’ main aim; 0 with a live phase 3 study; 0 primary completions in the next 12 months.

Comparator & background therapies

What other companies’ phase 2+ studies give as the comparator or the background here (its leading trial sponsor and partners left out): a sign of what new drugs are measured against, not by itself the standard of care, its prescriptions or its market.

DrugLeading trial sponsor · rightsCompanies, last 5 years
onabotulinum toxin ARecent, limitedPhase 4 trial recorded
Evidence
  • NCT06840158 · Innopharm LLC · Phase 3 · comparator · “BOTOX®” · registered Jan 2025
  • NCT02188277 · Merz Pharma · Phase 2 · comparator · “Botox®” · registered Jul 2014
AbbVie86% of its industry studies11 study

Programs

“Meets, by arms” reads each study’s arms: vs its arm against the therapy’s; + X vs a combination against it; added to it plus the therapy against the therapy; studied with given together only. The next primary completion is the next phase-3 study’s when there is one.

The 1 program — sign in to see the whole list, free: filter by phase and aim, sort by late development, direct comparisons or the next primary completion.

Primary completion in the next 12 months (0)

Live phase 2 and 3 studies of these programs. Primary completion is when the main measure’s data collection ends, as the registry states it (most are estimates); results come later, if they are announced.

None in the next 12 months.

Read from ClinicalTrials.gov, industry-led studies. Main aim: this is the study’s judged main condition; named, not the main aim: the sponsor names it, the study is about something else; registry mapping only: only the registry’s mapping put it here. Leading trial sponsor is the company leading the most industry studies of a drug, a measure of trial activity, not of rights. US and EU rights, and Approved: from the regulators’ records (FDA’s Drugs@FDA via openFDA; EMA’s medicines data) — the holder of a marketed or authorized original, generics and other companies’ versions; not rights elsewhere, nor approval for this condition. Phase 4 trial recorded, where neither lists it: a phase 4 study exists somewhere. Not read yet: labels by indication, exclusivity, licenses, line of therapy, academic comparators, sales.

What is being tested here

Drugs under test in Cerebral Palsy studies, those with the most open studies first. Medicines only given beside them are not counted. How drugs are counted

Drug classes tested here Local anesthetics 3 open · Antimuscarinics 1 open

Coming up

118studies finish main data collection within a year

Studies recruiting or running, from their records. “Main data collection” ends at the primary completion date, the sponsor’s own estimate, which often moves.

The 10 nearest

Who these studies take

Of the 270 Cerebral Palsy studies recruiting now, 27 (10%) set no upper age limit and 235 (87%) stop at 75 or younger. 255 (94%) take children under 18. 4 (1%) are for women only and 0 (0%) for men only; 53 (20%) take healthy volunteers.

Recruiting studies that take each age, of 270
AgeWomenMen
10192 (71%)189 (70%)
18112 (41%)109 (40%)
3048 (18%)45 (17%)
4046 (17%)43 (16%)
5041 (15%)39 (14%)
6538 (14%)36 (13%)
7535 (13%)33 (12%)
8529 (11%)27 (10%)

Across all 1,941 studies, recruiting or not: 92% stop at 75 or younger and 91% at 65; 94% take children; 1% are for women only and <1% for men only; 15% take healthy volunteers. From each study’s registry entry; the criteria on its page decide.

How long Cerebral Palsy studies take

Of 22 phase 1 interventional studies under Cerebral Palsy, half reached primary completion within 30 months of starting, counting those still running.

Start to primary completionEvery sponsorIndustryNon-industry
Phase 130 mo13–43 · 22 studies——
Phase 339 mo33–59 · 17 studies——
Interventional, no phase12 mo5–31 · 922 studies—12 mo5–31 · 903 studies
Observational21 mo8–60 · 220 studies—21 mo8–60 · 216 studies

Each figure is the month by which half the studies had reached primary completion, with the range in which the middle half did. Studies still running count until their last registry update; studies that stopped early are left out. Phase 1 includes early phase 1; observational means prospective or not stated, as retrospective and cross-sectional studies date a window of data rather than a study. How these figures are worked out

What changed recently

From the registry's own updates since Oct 18, 2026.

Results posted1

Newly registered22

Show 17 more

Studies

Recruiting first, then most recently updated. Showing 50 of 1,941. Browse all 1,941 → or search them.